References in periodicals archive ?
For for the most recent 12 months ending in July 2016, the Lamictal ODT brand and generic had US sales of approximately USD65.
In a statement today, the ministry refuted the media reports and said that it didn't receive any complaints signaling a shortage of Lamictal.
As reported in a special session at the annual meeting of the American Epilepsy Society in December, the findings from all three studies consistently and clearly showed that the generic lamotrigine products tested in these three studies all performed identically to Lamictal by both their pharmacokinetic profiles and in their clinical safety and efficacy.
If generic forms of lamotrigine behave indistinguishably from Lamictal, then it's very reasonable to expect that virtually any generic form of any brand name drug used in medicine is also a good mimic if it recently passed FDA muster.
The diagnosing and prescribing medical specialists involved in the case are now reassessing her mental health and are assisting to wean her off Lamictal under supervision.
Lamictal is part of the anti-seizure family of medications.
Glaxosmithkline updated the market with news that its epilepsy drug Lamictal XR had been approved in the United States.
Eurand received approval from the FDA for EUR-1048, to be marketed as GlaxoSmithKline's Lamictal ODT (lamotrigine) Orally Disintegrating Tablets.
Competition from generic rivals to the firm's key brands, such as bipolar and epilepsy treatment Lamictal, and ongoing weakness for its under-fire diabetes drug Avandia could have hit sales, according to Charles Stanley analyst Jeremy Batstone-Carr.
Competition from generic rivals to the firm's key brands, such as bipolar and epilepsy treatment Lamictal, and ongoing weakness for its under-fire diabetes drug, Avandia, could have hit sales, according to Charles Stanley analyst Jeremy Batstone-Carr.
Bipolar conditions have also gained clinical prominence thanks to the introduction two years ago of Lamictal (lamotrigine), an anticonvulsant drug that has been proven to delay the mood swings, especially the depressive ones, associated with bipolar disorder.
Shares in GlaxoSmithKline have been supported by a dozen products reaching the final stages of clinical trials and investors will look for positive sales growth for existing drugs including Advair and Lamictal.